Repatha Cost in Pennsylvania 2026: Price, Insurance, Medicaid, and Compounding Options

Evolocumab, sold under the brand name Repatha (Amgen), is an injectable monoclonal antibody in the PCSK9 inhibitor class, FDA-approved to lower LDL cholesterol in adults and some pediatric patients with familial hypercholesterolemia or established atherosclerotic cardiovascular disease. It is not a statin, not an oral drug, and not the same molecule as alirocumab (Praluent), a related but separate PCSK9 inhibitor.

For most Pennsylvania patients the manufacturer's list price is nearly irrelevant to what actually gets paid at the pharmacy. The number that matters is which of a small set of access pathways applies: commercial insurance with a manufacturer co-pay card, Medicaid with prior authorization, a manufacturer patient-assistance foundation, Medicare Part D under the federal out-of-pocket cap, or a compounded version from a state-licensed pharmacy. This article walks through each pathway and flags the specific facts a patient or prescriber should re-verify before acting on them, since insurer rules and prices change without notice while FDA approval and federal law change rarely.

What evolocumab does and why the price is high

Evolocumab is a fully human monoclonal antibody that blocks PCSK9, a liver protein that otherwise degrades LDL receptors. With PCSK9 blocked, more LDL receptors stay on the liver cell surface and pull more LDL cholesterol out of the bloodstream. The FDA prescribing information for Repatha lists the approved dosing as 140 mg subcutaneously every two weeks or 420 mg once monthly, and the approved populations as heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and established atherosclerotic cardiovascular disease as an adjunct to diet and maximally tolerated statin therapy.

The pivotal cardiovascular outcomes trial for evolocumab (commonly cited as the FOURIER trial) is widely reported to have shown a large reduction in LDL-C and a statistically significant reduction in major cardiovascular events in a large population with established atherosclerotic disease on background statin therapy. The exact percentages and hazard ratios attributed to that trial vary across secondary sources, and a specific number should be checked against the original New England Journal of Medicine publication or the FDA label rather than taken from this page, since the source material behind this figure could not be independently verified for this draft.

Monoclonal antibody biologics are manufactured differently than small-molecule pills like statins, and that manufacturing complexity is part of why evolocumab costs many times more per month than generic rosuvastatin or atorvastatin. Amgen lowered Repatha's list price around 2018 after payer resistance to the original launch price; the exact current list price should be confirmed directly, since manufacturers revise list prices periodically and this page's figure may be out of date by the time it is read.

What Pennsylvania patients actually pay

Cash pay, no insurance and no assistance program. A patient paying entirely out of pocket should expect to pay close to the full list price at a retail pharmacy, since evolocumab is a branded biologic with no generic or biosimilar currently on the market. Discount cards may shave off a modest amount but will not bring a biologic anywhere near statin-level pricing.

Commercially insured patients. Most commercial insurers place Repatha on a specialty drug tier, which typically means a higher co-pay or coinsurance than a standard generic tier, and almost always requires prior authorization before the plan will pay its share. Amgen offers a co-pay assistance program for commercially insured patients that can reduce out-of-pocket cost significantly for those who qualify; the current program terms, income rules, and annual cap should be confirmed directly through Amgen's patient support channels, since manufacturer program terms change.

Patients who cannot afford it even with insurance. Manufacturer patient-assistance foundations for uninsured or underinsured patients below a defined income threshold exist for many branded biologics, including evolocumab. Eligibility income cutoffs and application requirements should be verified directly with the foundation rather than assumed from a secondary source, since these thresholds are updated periodically against the federal poverty guidelines.

Medicare Part D patients. Under the Inflation Reduction Act, Medicare Part D enrollees face a federal annual out-of-pocket cap on covered Part D drugs, set at $2,000 starting in 2025 under the Inflation Reduction Act (confirm current details with CMS directly). For a Pennsylvania Medicare patient who would otherwise face large costs in the catastrophic coverage phase, this cap is a material and durable change. It does not, by itself, tell a patient what their monthly co-pay will be before they hit the cap; that depends on their specific Part D plan's formulary tier for Repatha, which should be confirmed with the plan directly. Patients on Medicare are generally not eligible for manufacturer commercial co-pay cards due to federal anti-kickback rules governing drugs paid for by government programs; a manufacturer patient-assistance foundation or the Part D Extra Help program are the relevant alternatives to ask about.

Pennsylvania Medicaid: what is established and what needs confirmation

Pennsylvania Medicaid (Medical Assistance) covers evolocumab, but prior authorization is required, and beneficiaries are generally enrolled through a managed care organization (such as Keystone First, AmeriHealth Caritas Pennsylvania, or UPMC for You) rather than fee-for-service Medicaid directly. Each MCO can layer its own step-therapy and documentation requirements on top of the state Medical Assistance formulary.

What is reasonably well established across Medicaid programs generally, and consistent with how PCSK9 inhibitors are handled nationally, is that approval typically requires documentation of a prior statin trial (often at high intensity), sometimes an ezetimibe trial, current LDL-C values, and a qualifying diagnosis of familial hypercholesterolemia or established cardiovascular disease. What is not something this page can state with confidence is the exact current LDL-C threshold, the exact list of accepted statin trials, or the exact appeal timeline used by any specific Pennsylvania MCO in 2026. Those details should come from the prescriber's office contacting the patient's specific MCO pharmacy department, or from the current Pennsylvania Department of Human Services Medical Assistance formulary and preferred drug list directly, since MCO criteria are revised on their own schedules and a secondary summary can go stale quickly.

Commercial insurance prior authorization in Pennsylvania

Major commercial insurers operating in Pennsylvania generally cover Repatha but require prior authorization and step therapy: documented trial of at least one high-intensity statin, often ezetimibe, and LDL-C above a guideline-based threshold before approval. Pennsylvania has a state law (commonly referenced as Act 68, the Health Care Access and Quality Act) that gives patients and providers a right to appeal insurer coverage denials, including an expedited pathway for urgent clinical situations. The exact appeal deadlines and expedited-review timeframes should be confirmed with the Pennsylvania Insurance Department rather than assumed from this summary, since this draft could not independently verify the specific numeric timelines cited in earlier versions of this content.

A commonly cited LDL-C threshold from the 2018 ACC/AHA cholesterol guideline is 70 mg/dL or higher in very-high-risk atherosclerotic cardiovascular disease patients on maximally tolerated statin plus ezetimibe, and some payers and specialist consensus documents use a lower threshold in patients with a recent acute coronary syndrome. Payers vary in which threshold they apply, and a patient's specific plan documentation is the authoritative source for which threshold governs their case.

Compounded evolocumab: legal status and what it does not have

Licensed 503A compounding pharmacies may legally prepare a patient-specific compounded version of a drug, including biologics, when a valid prescription exists and the pharmacy follows applicable sterile compounding standards, under FDA's compounding framework. This is legally distinct from a 503B outsourcing facility, which compounds in bulk for office use rather than for a specific named patient.

What this means in practice for a Pennsylvania patient: a state-licensed 503A pharmacy can, in principle, prepare compounded evolocumab for less than the branded list price. What it does not mean is that the compounded product has been reviewed by the FDA for safety, purity, or potency, or that it has been tested for bioequivalence against Repatha. Evolocumab is a subcutaneous injectable biologic, which raises additional sterility and stability considerations compared with a compounded oral tablet or capsule. A patient or prescriber considering this route should confirm the pharmacy's active Pennsylvania license, ask directly about its sterile compounding practices, and treat cost savings as a trade against unknown manufacturing consistency rather than as a free substitution for the approved product. Cash prices for compounded evolocumab vary by pharmacy and were not independently verified for this draft; specific price claims should be obtained directly from the compounding pharmacy rather than from a secondary source.

Telehealth prescribing in Pennsylvania

Pennsylvania permits telehealth prescribing of evolocumab by a Pennsylvania-licensed physician or advanced practice provider following an appropriate visit, generally requiring documentation of a current lipid panel, medication history, and clinical rationale for choosing a PCSK9 inhibitor over statin plus ezetimibe alone. Prior authorization submission does not require an in-person visit; a telehealth prescriber can submit the same documentation electronically through the relevant Medicaid or commercial plan portal. Claims about adherence outcomes specifically comparing telehealth-initiated versus in-office PCSK9 inhibitor prescribing were not independently verifiable from the material available for this draft and have been removed rather than restated with an unverified citation.

What is established, what is plausible, and what is not established

Established: Evolocumab's FDA-approved indications and dosing regimens, the existence of a federal $2,000 annual out-of-pocket cap for Medicare Part D covered drugs starting in 2025, the legal existence of 503A compounding pharmacies as a category distinct from 503B facilities, and the general fact that Pennsylvania Medicaid and commercial insurers require prior authorization for PCSK9 inhibitors.

Plausible but requiring current verification: The specific dollar list price of Repatha in 2026, the specific co-pay a given Pennsylvania patient will face on a specific commercial plan, the specific LDL-C threshold and step-therapy documentation a specific Pennsylvania MCO will accept, and the current cash price of compounded evolocumab at any given pharmacy.

Not established from the material available for this draft: Precise percentage risk reductions or hazard ratios from specific cardiovascular outcomes trials, a precise prior-authorization denial or appeal-success rate for PCSK9 inhibitors in Pennsylvania specifically, and any quoted guideline language attributed to a specific consensus document. These have been described only in general terms above, or removed, pending confirmation against the primary trial publications and guideline documents.

Verification checklist: stable facts versus date-sensitive facts for Repatha access in Pennsylvania

Use this checklist to distinguish which evolocumab information remains stable versus what requires verification before finalizing coverage or purchasing decisions.

Stable, federally or clinically anchored facts (unlikely to change month to month):

• Evolocumab's FDA-approved indications (HeFH, HoFH, established ASCVD) and its two approved dosing schedules, per the FDA label.
• The legal distinction between 503A patient-specific compounding and 503B outsourcing facility compounding under federal law.
• The existence of a federal $2,000 annual Part D out-of-pocket cap under the Inflation Reduction Act, effective 2025 onward (confirm current-year cap amount if reading this after 2026, since the cap can be adjusted).
• The general principle that manufacturer commercial co-pay cards cannot be used by patients on Medicare, Medicaid, or other government insurance, due to federal anti-kickback rules.

Date-sensitive facts that must be re-verified before acting (check directly with the source named):

• The current Repatha list price. Verify at repatha.com or with a pharmacy, not from this article.
• The current Amgen co-pay card cap and eligibility rules. Verify with Amgen patient support.
• The current Pennsylvania Medicaid MCO (Keystone First, AmeriHealth Caritas PA, UPMC for You, and others) prior authorization criteria and step-therapy requirements. Verify with the specific MCO's pharmacy department.
• The current commercial insurer's (Highmark, Independence Blue Cross, UPMC Health Plan, Aetna, Cigna, or other) specialty tier placement, co-pay amount, and prior authorization form. Verify with the specific plan.
• The current cash price and license status of any 503A compounding pharmacy being considered. Verify directly with the pharmacy and the Pennsylvania State Board of Pharmacy license lookup.
• Any specific appeal deadline or expedited-review timeframe under Pennsylvania insurance law. Verify with the Pennsylvania Insurance Department.

If a number in this article conflicts with what the reader is told directly by a payer, pharmacy, or manufacturer program, the direct source should govern, since coverage rules and prices are the parts of this topic most likely to have changed since this page was last reviewed.

When to involve a prescriber or seek urgent care

Starting or restarting evolocumab, adjusting statin therapy, or interpreting an LDL-C result are decisions that require an individual prescriber's judgment and should not be based on this article alone. A patient who misses doses, experiences an allergic reaction to an injection, or has new chest pain, weakness, or vision changes should contact their prescriber or seek urgent medical care rather than deciding how to proceed based on a cost or access guide.